Tetraphase Pharmaceuticals, Inc.
(NASDAQ : TTPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-3.24%18.401.8%$102.70m
UTHRUnited Therapeutics Corporation
-1.84%76.0814.3%$73.38m
JAZZJazz Pharmaceuticals Plc
-1.99%131.702.3%$67.63m
SAGESAGE Therapeutics, Inc.
-2.96%177.258.7%$65.79m
MDCOMedicines Company
-2.58%35.4621.8%$56.26m
ARQLArQule, Inc.
-4.00%10.070.7%$53.88m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.54%170.966.2%$51.44m
PRGOPerrigo Co. Plc
-0.96%44.086.8%$51.33m
ICPTIntercept Pharmaceuticals, Inc.
-1.83%79.9018.6%$49.26m
CTLTCatalent Inc
-0.98%52.722.4%$43.55m
HZNPHorizon Pharma plc
-1.26%23.476.7%$38.54m
ICLRICON Plc
0.62%148.554.1%$36.70m
ZYNEZynerba Pharmaceuticals Inc
-2.55%13.008.3%$28.30m
AXSMAxsome Therapeutics, Inc.
-3.62%23.302.1%$27.69m
PTLAPortola Pharmaceuticals, Inc.
-4.20%26.267.5%$27.00m

Company Profile

Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.